Literature DB >> 30416750

Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.

Greta Del Mistro1,2, Philippe Lucarelli3, Ines Müller1,2, Sébastien De Landtsheer3, Anna Zinoveva1,2, Meike Hutt4, Martin Siegemund4, Roland E Kontermann4,5, Stefan Beissert1, Thomas Sauter3, Dagmar Kulms1,2.   

Abstract

Metastatic melanoma remains a life-threatening disease because most tumors develop resistance to targeted kinase inhibitors thereby regaining tumorigenic capacity. We show the 2nd generation hexavalent TRAIL receptor-targeted agonist IZI1551 to induce pronounced apoptotic cell death in mutBRAF melanoma cells. Aiming to identify molecular changes that may confer IZI1551 resistance we combined Dynamic Bayesian Network modelling with a sophisticated regularization strategy resulting in sparse and context-sensitive networks and show the performance of this strategy in the detection of cell line-specific deregulations of a signalling network. Comparing IZI1551-sensitive to IZI1551-resistant melanoma cells the model accurately and correctly predicted activation of NFκB in concert with upregulation of the anti-apoptotic protein XIAP as the key mediator of IZI1551 resistance. Thus, the incorporation of multiple regularization functions in logical network optimization may provide a promising avenue to assess the effects of drug combinations and to identify responders to selected combination therapies.

Entities:  

Year:  2018        PMID: 30416750      PMCID: PMC6218484          DOI: 10.1038/s41540-018-0075-y

Source DB:  PubMed          Journal:  NPJ Syst Biol Appl        ISSN: 2056-7189


  43 in total

Review 1.  Resistance to BRAF-targeted therapy in melanoma.

Authors:  Ryan J Sullivan; Keith T Flaherty
Journal:  Eur J Cancer       Date:  2013-01-02       Impact factor: 9.162

2.  C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer.

Authors:  Fenglin Zang; Xiyin Wei; Xue Leng; Man Yu; Baocun Sun
Journal:  Biochem Biophys Res Commun       Date:  2014-06-06       Impact factor: 3.575

Review 3.  Caspase-8: regulating life and death.

Authors:  Bart Tummers; Douglas R Green
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 4.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

5.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

6.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 7.  The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.

Authors:  Kim Margolin
Journal:  Curr Treat Options Oncol       Date:  2016-09

8.  NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma.

Authors:  Yongping Shao; Kaitlyn Le; Hanyin Cheng; Andrew E Aplin
Journal:  J Invest Dermatol       Date:  2015-03-09       Impact factor: 8.551

9.  High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.

Authors:  L Flanagan; J Kehoe; J Fay; O Bacon; A U Lindner; E W Kay; J Deasy; D A McNamara; J H M Prehn
Journal:  Radiat Oncol       Date:  2015-06-13       Impact factor: 3.481

Review 10.  Three-dimensional cell culture: a breakthrough in vivo.

Authors:  Delphine Antoni; Hélène Burckel; Elodie Josset; Georges Noel
Journal:  Int J Mol Sci       Date:  2015-03-11       Impact factor: 5.923

View more
  3 in total

1.  A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.

Authors:  Shuyong Zhang; Chao Zheng; Wan Zhu; Peng Xiong; Dongdong Zhou; Changjiang Huang; Dexian Zheng
Journal:  Theranostics       Date:  2019-07-13       Impact factor: 11.556

2.  RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human β cells.

Authors:  Dimitri Van Simaeys; Adriana De La Fuente; Serena Zilio; Alessia Zoso; Victoria Kuznetsova; Oscar Alcazar; Peter Buchwald; Andrea Grilli; Jimmy Caroli; Silvio Bicciato; Paolo Serafini
Journal:  Nat Commun       Date:  2022-04-05       Impact factor: 17.694

Review 3.  Computational models of melanoma.

Authors:  Marco Albrecht; Philippe Lucarelli; Dagmar Kulms; Thomas Sauter
Journal:  Theor Biol Med Model       Date:  2020-05-14       Impact factor: 2.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.